Ciprofloxacin News and Research

RSS
Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Actavis to purchase four currently marketed products from Akorn

Actavis to purchase four currently marketed products from Akorn

Emergence of community-acquired infections due to ESBL-producing bacteria on the rise

Emergence of community-acquired infections due to ESBL-producing bacteria on the rise

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Diabetic patients taking oral fluoroquinolones may have high risk of severe blood sugar-related problems

Diabetic patients taking oral fluoroquinolones may have high risk of severe blood sugar-related problems

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

Teva to present abstracts on AZILECT at MDS meeting

Teva to present abstracts on AZILECT at MDS meeting

Drug targeting of phages could offer a potential new path to mitigate antibiotic resistance

Drug targeting of phages could offer a potential new path to mitigate antibiotic resistance

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Report highlights ecological cost of pharmaceutical waste

Report highlights ecological cost of pharmaceutical waste

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Less is more when it comes to antibiotics for UTI in men

Less is more when it comes to antibiotics for UTI in men

Less is more when it comes to antibiotics for UTI in men

Less is more when it comes to antibiotics for UTI in men

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Ciprofloxacin use is major contributor to MRSA spread in hospitals

Ciprofloxacin use is major contributor to MRSA spread in hospitals

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea